Fanconi anemia
Fanconi anemia
Updated: 7/9/2024
© Jun Wang, MD, PhD
General features
- Most common form of inherited aplastic anemia
- Autosomal recessive
- Approximately 25% of aplastic anemia
- Associated with cytopenias, predisposition to malignancy, and congenital and developmental abnormalities
Major causes
- Mutations in one of over 22 genes, FANCA to FANCW
- Most commonly mutated genes: FANCA, FANCC, and FANDG
Key pathogenesis
- Biallelic mutations of FANCA, FANCC, and FANCG most common
- Heterozygous FA mutations considered asymptomatic carriers, except
o FANCB (X-linked recessive)
o FANCR (autosomal dominant)
o FANCS and FANCD1 (AKA BRCA1 and BRCA2, respectively)
- Defects in DNA interstrand crosslink repair
- Cells highly vulnerable to endogenous injuries, such as ROS
- Anemia associated with selective destruction of CD34+ stem cells
Key clinical findings
- Early onset with concurrent birth defects
- Cytopenia/bone marrow failure
o Macrocytic anemia
o Thrombocytopenia: bleeding
o Neutropenia infections
o Pancytopenia
- May transform into Myelodysplastic syndrome (MDS), or Acute myeloid leukemia (AML) and related neoplasmsHigh risk for other tumors
- Endocrine disorders including thyroid, adrenal, gonadal, islets dysfunction and dyslipidemias
- Birth defects: short stature, microcephaly, microphthalmia, epicanthal folds, dangling thumbs, site of ureteral reimplantation, congenital dislocated hips, and rocker bottom feet
Key Laboratory findings
- Blood: Cytopenia including macrocytic anemia, thrombocytopenia, leukopenia or pancytopenia
- Bone marrow
o Hypocellular
o Loss of myeloid and erythroid precursors
o Loss of megakaryocytes
o Relative lymphocytosis
o Severe cases with fatty changes
o Features of MDS or leukemia
Diagnosis
- Based on findings of chromosome breaks, or FA mutations
- Indications for screening
o Persistent moderate to severe cytopenias: >2 weeks of moderate or severe cytopenias in ≥2 lineages with severely hypocellular bone marrow, without any known cause
o Characteristic physical findings: ≥3 of the following: vertebral anomalies, anal atresia, congenital heart disease, tracheoesophageal fistula, esophageal atresia, renal anomalies, limb anomalies, and hydrocephalus) or multiple malformations, such as short stature, cafĂ©-au-lait spots, thumb/radial ray abnormalities, or hypospadias that are strongly associated with FA
o Relative with FA patients
o Unexplained cytopenias associated with characteristic congenital abnormalities
o Individuals ≤40 years with MDS, AML, or certain cytogenetic abnormalities
o Squamous cell cancer (SCC) of the head, neck, or anorectal region with no known attributable exposure
o Patients who had severe toxicity with chemotherapy or radiation therapy
Management
- Supportive: transfusion
- Hematopoietic stem cell transplantation
- MDS or leukemia may be treated or prevented by hematopoietic stem cell transplantation
- Androgens if stem cell transplantation not an option
- Treatments of concurrent defects or disorders
Prognosis
- Death due to bleeding or infection
- Incidence of solid tumor rising due to improvement of survival
Back to anemia
Back to contents
Comments
Post a Comment